Table 1 Baseline characteristics (categorial) of non-pregnant vs. pregnant BC patients

From: Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification

Parameter

Category

Non-pregnant N = 125, N (%)

Pregnant N = 125, N (%)

Overall N = 250, N (%)

P value

Age at diagnosis, years

18–29

5 (4.0)

14 (11.2)

19 (7.6)

<0.001

30–34

32 (25.6)

56 (44.8)

88 (35.2)

 

35–39

51 (40.8)

44 (35.2)

95 (38.0)

 

≥40

37 (29.6)

11 (8.8)

48 (19.2)

 

HR status combined**

ER and PR negative

50 (40.0)

52 (41.6)

102 (40.8)

0.898

ER and/or PR positive

75 (60.0)

73 (58.4)

148 (59.2)

 

HER2 status**

Negative

98 (81.0)

95 (78.5)

193 (79.8)

0.749

Positive

23 (19.0)

26 (21.5)

49 (20.2)

 

Missing

4

4

8

 

Biological subtype**

TNBC

44 (35.2)

45 (36.0)

89 (35.6)

0.989

HER2 + /HR−

6 (4.8)

7 (5.6)

13 (5.2)

 

HER2 + /HR+

19 (15.2)

19 (15.2)

38 (15.2)

 

HER2-/HR+

56 (44.8)

54 (43.2)

110 (44.0)

 

Histological tumor type**

Ductal or ductal-lobular invasive

101 (80.8)

111 (90.2)

212 (85.5)

0.058

Lobular invasive

9 (7.2)

7 (5.7)

16 (6.5)

 

Other

15 (12.0)

5 (4.1)

20 (8.1)

 

Missing

0

2

2

 

Tumor grading**

G1

1 (0.8)

1 (0.8)

2 (0.8)

0.991

G2

40 (32.0)

39 (31.2)

79 (31.6)

 

G3

84 (67.2)

85 (68.0)

169 (67.6)

 

T stage*

T1

38 (30.4)

38 (30.4)

76 (30.4)

0.947

T2

65 (52.0)

63 (50.4)

128 (51.2)

 

T3

17 (13.6)

17 (13.6)

34 (13.6)

 

T4

5 (4.0)

7 (5.6)

12 (4.8)

 

N stage*

N0

0 (0.0)

58 (46.4)

58 (23.2)

<.001

N1

89 (71.2)

47 (37.6)

136 (54.4)

 

N2

16 (12.8)

14 (11.2)

30 (12.0)

 

N3

20 (16.0)

6 (4.8)

26 (10.4)

 

Ki-67**, at diagnosis

≤20%

70 (61.9)

56 (46.7)

126 (54.1)

0.025

>20%

43 (38.1)

64 (53.3)

107 (45.9)

 

Missing

12

5

17

 

Pregnancy trimester

1st trimester

0 (n.a.)

23 (18.5)

23 (18.5)

n.a.

2nd trimester

0 (n.a.)

43 (34.7)

43 (34.7)

 

3rd trimester

0 (n.a.)

58 (46.8)

58 (46.8)

 

Missing

125

1***

126

 
  1. *pT resp. pN, if not available cT and cN; **assessed from stained TMAs (via IHC) by the central pathology, Marburg; *** in 1 patient BC was histologically diagnosed 6 days postpartum; data are N (valid %).